Cipla’s contraceptive drug approved
Drug firm Cipla on Monday said it has received final nod from the US health regulator for its Medroxyprogesterone injectable for prevention of pregnancy. The company has received final approval from the United States Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Medroxyprogesterone injectable 150mg/mL. The product is a generic version of Pfizer’s Depo-Provera, it added. Depo-Provera and its generic equivalents had US sales of around $159 million for the 12-month period ending November 2018, Cipla further said. The injection is indicated only for the prevention of pregnancy.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.